Terms: = Gastric cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
12 results:
1. OCT4-mediated transcription confers oncogenic advantage for a subset of gastric tumors with poor clinical outcome.
Pandian J; Panneerpandian P; Sekar BT; Selvarasu K; Ganesan K
Funct Integr Genomics; 2022 Dec; 22(6):1345-1360. PubMed ID: 35987846
[TBL] [Abstract] [Full Text] [Related]
2. Identified a disintegrin and metalloproteinase with thrombospondin motifs 6 serve as a novel gastric cancer prognostic biomarker by bioinformatics analysis.
Zhu YZ; Liu Y; Liao XW; Luo SS
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33851708
[TBL] [Abstract] [Full Text] [Related]
3. Amplification of kras and its heterogeneity in non-Asian gastric adenocarcinomas.
Rehkaemper J; Korenkov M; Quaas A; Rueschoff J; Pamuk A; Zander T; Hillmer AM; Buettner R; Hoelscher AH; Bruns CJ; Loeser H; Alakus H; Schoemig-Markiefka B
BMC Cancer; 2020 Jun; 20(1):587. PubMed ID: 32571252
[TBL] [Abstract] [Full Text] [Related]
4. A Comprehensive PDX gastric cancer Collection Captures cancer Cell-Intrinsic Transcriptional MSI Traits.
Corso S; Isella C; Bellomo SE; Apicella M; Durando S; Migliore C; Ughetto S; D'Errico L; Menegon S; Moya-Rull D; Cargnelutti M; Capelôa T; Conticelli D; Giordano J; Venesio T; Balsamo A; Marchiò C; Degiuli M; Reddavid R; Fumagalli U; De Pascale S; Sgroi G; Rausa E; Baiocchi GL; Molfino S; Pietrantonio F; Morano F; Siena S; Sartore-Bianchi A; Bencivenga M; Mengardo V; Rosati R; Marrelli D; Morgagni P; Rausei S; Pallabazzer G; De Simone M; Ribero D; Marsoni S; Sottile A; Medico E; Cassoni P; Sapino A; Pectasides E; Thorner AR; Nag A; Drinan SD; Wollison BM; Bass AJ; Giordano S
Cancer Res; 2019 Nov; 79(22):5884-5896. PubMed ID: 31585941
[TBL] [Abstract] [Full Text] [Related]
5. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract] [Full Text] [Related]
6. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract] [Full Text] [Related]
7. A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.
Liu X; Guo W; Zhang W; Yin J; Zhang J; Zhu X; Liu T; Chen Z; Wang B; Chang J; Lv F; Hong X; Wang H; Wang J; Zhao X; Wu X; Li J
BMC Cancer; 2017 Mar; 17(1):188. PubMed ID: 28288572
[TBL] [Abstract] [Full Text] [Related]
8. Bladder and gastric metastases from lung adenocarcinoma harboring codon 13 kras mutation: a case report with unusual clinical outcome.
Galetta D; Catino A; Misino A; De Ceglie A; Logroscino A; Simone G; Natalicchio MI
Tumori; 2015 Sep; 101(5):e138-40. PubMed ID: 26045124
[TBL] [Abstract] [Full Text] [Related]
9. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Luber B; Deplazes J; Keller G; Walch A; Rauser S; Eichmann M; Langer R; Höfler H; Hegewisch-Becker S; Folprecht G; Wöll E; Decker T; Endlicher E; Lorenzen S; Fend F; Peschel C; Lordick F
BMC Cancer; 2011 Dec; 11():509. PubMed ID: 22152101
[TBL] [Abstract] [Full Text] [Related]
10. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Wainberg ZA; Lin LS; DiCarlo B; Dao KM; Patel R; Park DJ; Wang HJ; Elashoff R; Ryba N; Hecht JR
Br J Cancer; 2011 Sep; 105(6):760-5. PubMed ID: 21811258
[TBL] [Abstract] [Full Text] [Related]
11. Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer.
Li M; Liu W; Zhu YF; Chen YL; Zhang BZ; Wang R
Acta Oncol; 2006; 45(8):1115-9. PubMed ID: 17118848
[TBL] [Abstract] [Full Text] [Related]
12. DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridonale (GDIM) prospective study.
Russo A; Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Latteri F; Valerio MR; Pantuso G; Morello V; Dardanoni G; Latteri MA; Colucci G; Tomasino RM; Gebbia N
Cancer; 2001 Jul; 92(2):294-302. PubMed ID: 11466682
[TBL] [Abstract] [Full Text] [Related]
